DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
about
Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritisInterpreting radiographic data in rheumatoid arthritis.Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathwayAuranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucytotic gold ions.
P2860
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@ast
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@en
type
label
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@ast
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@en
prefLabel
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@ast
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@en
P1476
DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
@en
P2093
P304
P577
2000-05-01T00:00:00Z